Company profilePharmaceutical#737 of 1,318 in Pakistan✓ No DRAP alerts

Merixil Pharma

Pharmaceutical company · 12 brands · 10 molecules

12 registered products 13 pharmaceutical brands 10 distinct molecules 0 DRAP alerts

Company overview

12
registered products
13
pharmaceutical brands
10
distinct molecules
0
therapeutic classes
0
DRAP alerts

Merixil Pharma is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 12 product registrations across 10 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Paclitaxel3 brands
Docetaxel2 brands
Rhug-Csf) ...... 3000 Μg1 brand
Filgrastim (Recombinant Human Granulocyte Colony-Stimulating Factor Injection1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official12 products · Rs 1,384.94 – Rs 64,630.49
Median across source: Rs 15,679.88

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for Merixil

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.